Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET

Company Participants

Kim Golodetz - Alliance Advisors IR
Stacy Lindborg - President & Chief Executive Officer
David Gaiero - Interim Chief Financial Officer
Michael Tardugno - Executive Chairman

Conference Call Participants

David Bautz - Zacks
Kemp Dolliver - Brookline Capital Markets
James Molloy - Alliance Global Partners

Operator

Hello everyone. Good morning. My name is Malone, and I will be your operator today. At this time, I would like to welcome you to Imunon's Third Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. Following the speakers prepared remarks; there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Kim Golodetz. Please go ahead.

Kim Golodetz

Thank you and good morning everyone. This is Kim Golodetz with Alliance Advisors IR. Welcome to Imunon's third quarter 2024 financial results and business update conference call.

During today's call, management will be making forward-looking statements regarding Imunon's expectations and projections about future events. In general, forward-looking statements can be identified by words, such as expects, anticipates, believes or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission.

No forward-looking statements can be guaranteed and actual results may differ materially from such statements. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, November 7, 2024. Imunon undertakes no obligation to revise or update comments made during this call, except as required by law.

With that said, I would like to turn the call over to Dr. Stacy Lindborg, Imunon's President and Chief Executive Officer. Stacy?

Stacy Lindborg

Thank you, Kim, and good morning everybody. I'd like to begin by noting that Michael Tardugno, the Executive Chairman of our Board; and Khursheed Anwer, our Chief Scientific Officer are both on the line and will be available for Q&A. David Gaiero, our Interim Chief Financial Officer will review our financial results following my remarks.

Let me start with the punch line and a groundbreaking milestone for Imunon. On July 30th, we announced the results from our large randomized Phase 2 study OVATION 2, which has the potential to set a new standard in cancer research. This large randomized study involving 112 newly diagnosed patients with advanced ovarian cancer, not only exceeds expectations, but also marks an unprecedented achievement in oncology, an improvement in median overall survival 11.1 months, nearly a year compared to the standard of care, a clinically meaningful and unprecedented improvement in first line treatment.